ZLD.AX - Zelira Therapeutics Limited
| Previous close | 0.9400 |
| Open | 0.9100 |
| Bid | 0.9500 x 14831600 |
| Ask | 0.9000 x 5161300 |
| Day's range | 0.9000 - 0.9400 |
| 52-week range | 0.9000 - 5.0000 |
| Volume | |
| Avg. volume | 4,311 |
| Market cap | 10.666M |
| Beta (5Y monthly) | 1.33 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.0800 |
| Earnings date | 29 Aug 2023 - 04 Sept 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireZelira Therapeutics Launches ZYRAYDI™ B2B Technology to Create Pharma-grade Cannabis Capsules & Tablets for Global Markets
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), a global leader in the research, development and commercialization of clinically validated cannabinoid medicines, is pleased to announce the launch of ZYRAYDI™, its patented, licensable technology for the future of the medical cannabis industry.
- PR Newswire
Zelira's Zenivol™, the World's First Clinically Validated Cannabinoid Medication for Insomnia, Achieves Regulatory Approval in Germany
Zelira Therapeutics Ltd (ASX: ZLD, OTC-QB: ZLDAF), a global leader in the research, development and commercialization of clinically validated cannabinoid medicines, is pleased to announce that its groundbreaking insomnia medication Zenivol™ has achieved formal approval from German regulatory authority BfArM to launch in the German medical cannabis market.
Simply Wall St.We're Keeping An Eye On Zelira Therapeutics' (ASX:ZLD) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although...